OTCPK:QTVL.F

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

QT Vascular Ltd., together with its subsidiaries, engages in the design, assembly, and distribution of advanced therapeutic solutions for the minimally invasive treatment of complex vascular diseases. More Details


Snowflake Analysis

Overvalued with worrying balance sheet.

Share Price & News

How has QT Vascular's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: QTVL.F's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

QTVL.F

-2.5%

US Medical Equipment

-3.1%

US Market


1 Year Return

n/a

QTVL.F

14.6%

US Medical Equipment

12.7%

US Market

Return vs Industry: Insufficient data to determine how QTVL.F performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how QTVL.F performed against the US Market.


Shareholder returns

QTVL.FIndustryMarket
7 Day0%-2.5%-3.1%
30 Day0%-0.06%-2.9%
90 Day250.0%13.9%8.2%
1 Yearn/a15.6%14.6%15.3%12.7%
3 Year-29.8%-29.8%71.4%67.0%37.8%28.5%
5 Year-95.0%-95.0%149.1%130.4%90.9%69.4%

Price Volatility Vs. Market

How volatile is QT Vascular's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is QT Vascular undervalued compared to its fair value and its price relative to the market?

3.14x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate QTVL.F's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate QTVL.F's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: QTVL.F is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: QTVL.F is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate QTVL.F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: QTVL.F is good value based on its PB Ratio (3.1x) compared to the US Medical Equipment industry average (3.7x).


Next Steps

Future Growth

How is QT Vascular forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

26.0%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as QT Vascular has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of QTVL.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on theOTC Markets Website. If you are looking for more of a qualitative research into the company, you can access QT Vascular's filings and announcementshere.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has QT Vascular performed over the past 5 years?

40.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: QTVL.F is currently unprofitable.

Growing Profit Margin: QTVL.F is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: QTVL.F is unprofitable, but has reduced losses over the past 5 years at a rate of 40.3% per year.

Accelerating Growth: Unable to compare QTVL.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: QTVL.F is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.2%).


Return on Equity

High ROE: QTVL.F has a negative Return on Equity (-236.85%), as it is currently unprofitable.


Next Steps

Financial Health

How is QT Vascular's financial position?


Financial Position Analysis

Short Term Liabilities: QTVL.F's short term assets ($1.2M) do not cover its short term liabilities ($6.3M).

Long Term Liabilities: QTVL.F's short term assets ($1.2M) exceed its long term liabilities ($66.0K).


Debt to Equity History and Analysis

Debt Level: QTVL.F's debt to equity ratio (49.7%) is considered high.

Reducing Debt: QTVL.F's debt to equity ratio has increased from 0.6% to 49.7% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: QTVL.F has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: QTVL.F has less than a year of cash runway if free cash flow continues to grow at historical rates of 18.4% each year.


Next Steps

Dividend

What is QT Vascular current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate QTVL.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate QTVL.F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if QTVL.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if QTVL.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of QTVL.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

7.1yrs

Average board tenure


CEO

Eitan Konstantino (52 yo)

7.67yrs

Tenure

Dr. Eitan Konstantino, Ph.D. Co-founded TriReme Medical LLC in 2005 and serves as its Chief Executive Officer & President. Dr. Konstantino is Chief Executive Officer of QT Vascular Ltd. since 2013 and has ...


Board Members

NamePositionTenureCompensationOwnership
Eitan Konstantino
CEO & Executive Director7.67yrsno data0.41%
$ 47.1k
Mark Allen Wan
Non-Independent Non-Executive Director7.17yrsno datano data
Gregory David Casciaro
Independent Director7.08yrsno data0.075%
$ 8.6k
Amir Belson
Independent Chairman2.25yrsno data0.14%
$ 16.2k
Kian Hin Sho
Independent Director5yrsno data0%
$ 0

7.1yrs

Average Tenure

54yo

Average Age

Experienced Board: QTVL.F's board of directors are considered experienced (7.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: QTVL.F insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

QT Vascular Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: QT Vascular Ltd.
  • Ticker: QTVL.F
  • Exchange: OTCPK
  • Founded: 2005
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: S$15.647m
  • Listing Market Cap: S$11.459m
  • Shares outstanding: 2.24b
  • Website: https://www.qtvascular.com

Number of Employees


Location

  • QT Vascular Ltd.
  • 3A International Business Park
  • No. 09-12 ICON @ IBP Tower B
  • Singapore
  • 609935
  • Singapore

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
5I0Catalist (Singapore Exchange Catalist Market)YesOrdinary SharesSGSGDApr 2014
QTVL.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDApr 2014

Biography

QT Vascular Ltd., together with its subsidiaries, engages in the design, assembly, and distribution of advanced therapeutic solutions for the minimally invasive treatment of complex vascular diseases. The ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/23 05:48
End of Day Share Price2020/09/02 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.